Department of Medicine

University of Pittsburgh

Liza C. Villaruz, MD

photo

Assistant Professor of Medicine

Division of Hematology/Oncology

Office: UPMC Cancer Pavilion
5150 Centre Avenue, 5th Floor
Pittsburgh, PA 15232
 
Phone: 412-648-6578
Fax: 412-648-6579
E-mail: villaruzl@upmc.edu
Find A Doctor UPMC Profile

Education
BS, University of Notre Dame, Notre Dame, IN, 2001
MD, University of Maryland School of Medicine, 2005

Training
Internal Medicine Residency, University of Pittsburgh Medical Center, 2008
Hematology/Oncology Fellowship, University of Pittsburgh Cancer Institute, 2011

Area of Specialization/Research Interest  
Lung Cancer
Novel Therapies in Lung Cancer
Clinical Trials in Lung Cancer
 

Profile
Liza C. Villaruz, MD, is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine in the Division of Hematology/Oncology. She is board-certified in internal medicine, medical oncology and hematology. Dr. Villaruz's clinical expertise and research focuses on the evaluation and management of lung cancer and other thoracic malignancies. As an active member of the Lung and Thoracic Malignancies Program and the University of Pittsburgh’s Specialized Program of Research Excellence (SPORE) in lung cancer, Dr. Villaruz actively accrues and is the principal investigator of several ongoing clinical trials at the University of Pittsburgh Cancer Institute evaluating novel therapeutic approaches to the treatment of lung cancer. Her research focuses on delineating the clinical behavior of novel molecular subtypes of lung cancer, and the study of novel targeted agents for the treatment of these lung cancer molecular subtypes. She has been awarded the Conquer Cancer Foundation of ASCO Young Investigator Award for her work on the role of microRNAs as biomarkers of chemotherapy resistance in metastatic melanoma. Dr. Villaruz received an undergraduate degree in biology at the University of Notre Dame, in Notre Dame, IN, and a medical degree at the University of Maryland School of Medicine, in Baltimore, MD. She completed her residency in internal medicine and her fellowship in hematology/oncology at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Dr. Villaruz is a member of the American Society of Clinical Oncology and is an invited reviewer for medical journals such as Lung Cancer and Oncology Research.

Recent Grants
Title: Conquer Cancer Foundation of ASCO 2011 Young Investigator Award
Role: PI
Amount: $50,000
Funding Agency: Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)
Start Year: 2011
End Year: 2012

Recent Peer-Reviewed Publications
Title: The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
Author(s): Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S
Year: 2013
Journal: Cancer
Volume: 119
Page(s): 2268-74
Title: The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.
Author(s): Villaruz LC, Socinski MA
Year: 2013
Journal: Clin Cancer Res
Volume: 19
Page(s): 2629-36
Title: Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).
Author(s): Yazbeck VY, Villaruz L, Haley M, Socinski MA
Year: 2013
Journal: Cancer J
Volume: 19
Page(s): 231-7
Title: Management of non-small cell lung cancer with oligometastasis.
Author(s): Villaruz LC, Kubicek G, Socinski MA
Year: 2012
Journal: Curr Oncol Rep.
Volume: 14
Page(s): 333-41
Title: Personalized therapy for non-small cell lung cancer: which drug for which patient?
Author(s): Villaruz LC, Socinski MA
Year: 2011
Journal: Semin Thoracic Surg.
Volume: 23
Page(s): 281-90
Title: Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Author(s): Tawbi HA, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, Shipe-Spotloe J, Radkowski R, Kirkwood JM
Year: 2011
Journal: Br J Cancer
Volume: 105
Page(s): 773-7
For Pub Med search results, click here.